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Abstract
Aims: Sirtuins, a family of NAD+-dependent deacetylases, are recognized as nondispensable regulators of aging
processes. Sirtuin 3 (SIRT3) is the main mitochondrial deacetylase that maintains mitochondrial bioenergetics,
an essential prerequisite for healthy aging. In this study, using Sirt3 knockout (Sirt3-/-) mice, we sought to
establish whether Sirt3 deficiency affected life span, an endpoint that has never been tested formally in
mammals, and uncover the mechanisms involved in organ damage associated with aging.
Results: Sirt3-/- mice experienced a shorter life span than wild-type mice and severe cardiac damage, char-
acterized by hypertrophy and fibrosis, as they aged. No alterations were found in organs other than the heart.
Sirt3 deficiency altered cardiac mitochondrial bioenergetics and caused hyperacetylation of optic atrophy 1
(OPA1), a SIRT3 target. These changes were associated with aberrant alignment of trans-mitochondrial cristae
in cardiomyocytes, and cardiac dysfunction. Gene transfer of deacetylated Opa1 restored cristae alignment in
Sirt3-/- mice, ameliorated cardiac reserve capacity, and protected the heart against hypertrophy and fibrosis.
The translational relevance of these findings is in the data showing that SIRT3 silencing in human-induced
pluripotent stem cell-derived cardiomyocytes led to mitochondrial dysfunction and altered contractile pheno-
type, both rescued by Opa1 gene transfer.
Innovation: Our findings indicate that future approaches to heart failure could include SIRT3 as a plausible
therapeutic target.
Conclusion: SIRT3 has a major role in regulating mammalian life span. Sirt3 deficiency leads to cardiac
abnormalities, due to defective trans-mitochondrial cristae alignment and impaired mitochondrial bioenergetics.
Correcting cardiac OPA1 hyperacetylation through gene transfer diminished heart failure in Sirt3-/- mice
during aging. Antioxid. Redox Signal. 31, 1255–1271.
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S irtuins (SIRTs) are an evolutionary conserved family ofNAD+-dependent deacetylases that regulate multiple
cellular processes, including stress resistance, apoptosis, in-
flammation, and mitochondrial energy homeostasis, and are
recognized as critical determinants in counteracting the aging
process and age-related diseases (19, 27).
In mammals, three members of the SIRT family— sirtuin 3
(SIRT3), SIRT4, and SIRT5—are localized in the mito-
chondrial matrix and modulate mitochondrial metabolism,
but it is SIRT3 that functions uniquely as a major regulator of
the whole organelle acetylome (33, 42). In fact, in mice the
deletion of Sirt3, but not of Sirt4 or Sirt5, resulted in striking
global hyperacetylation of mitochondrial proteins (25), in-
dicating that SIRT3 is central to mitochondrial deacetylase
activity, which is an essential prerequisite for healthy aging
(52). Indeed, almost 60% of mitochondrial proteins can be
deacetylated quickly to meet cellular metabolic demands
and contribute substantially to maintaining bioenergetic
adaptation during aging (16).
In this context, it has been demonstrated that SIRT3 fine-
tunes the process of energy production, due to its primary role
in fatty acid oxidation through the deacetylation of long-
chain acyl-CoA dehydrogenase (17), as well as the activation
of mitochondrial enzymatic chain proteins, including com-
plexes I (2), II (14), and V (39), which are involved in oxi-
dative phosphorylation through which ATP is generated.
In addition to energy supply and nutrient oxidation, SIRT3
affects other major aspects of mitochondrial biology, in-
cluding reactive oxygen species detoxification and mito-
chondrial dynamics (6, 31, 35). Sirt3 attenuation or ablation
is known to be associated with the accelerated development
of several diseases of aging, including cancer and cardio-
vascular, renal, hepatic, and neurodegenerative disorders (5,
18, 20, 29, 32, 34, 43). Features that are characteristic of
aging are found in the myocardium of Sirt3 heart-specific
knockout mice, such as mitochondrial protein dysfunction,
enhanced oxidative stress, and impaired energy metabolism
(24). Whether sequelae of SIRT3 deficiency translated into an
effect on life span was not addressed.
In this study, we wanted (i) to investigate the impact that
the lack of Sirt3 had on life span in mice, which, surprisingly,
had not been studied in mammals yet; (ii) to establish which
organ is primarily affected by Sirt3 deficiency during aging,
and identify the molecular mechanisms underlying organ
dysfunction in aged mice; (iii) to mitigate target organ dys-
function therapeutically; and (iv) to demonstrate the transla-
tional relevance of these findings by studying SIRT3-silenced
human-induced pluripotent stem cell (iPSC)-derived cardio-
myocytes in vitro.
Results
Sirt3 deficiency shortens life span and promotes
cardiac dysfunction
We set out to examine the impact of Sirt3 gene disruption
in male mice compared with wild type (WT) control litter-
mates. All Sirt3 knockout animals died within 34 months, at
which time 28% of their control littermates were still alive
(Fig. 1). Log-rank test analysis showed significant differ-
ences in the survival curves between Sirt3-/- and WT mice.
Compared with WT littermates, the median life span of
Sirt3-/- mice was 19% shorter (median = 50th percentile:
from 32 to 26 months) ( p-value of <0.0001, Fig. 1). Com-
pared with WT littermates, the maximum life span of Sirt3-/-
mice (i.e., the life span of the oldest 10% of a cohort to die)
was 10% shorter (90th percentile: from 35.5 to 32 months), a
p-value of 0.011.
Of all the organs analyzed in aged mice in the present
study, the heart was the main organ affected by Sirt3 defi-
ciency. Aged Sirt3-/-mice developed severe cardiac damage,
characterized by hypertrophy and fibrosis, which is in line
with previous studies (15, 45, 46). An increased heart to body
weight ratio (Fig. 2A) and the accumulation of collagen de-
position in the interstitial space (Fig. 2B, C) were observed in
aged Sirt3-/- but not in WT mice.
A similar number of immune cells were found in the car-
diac tissue of Sirt3-/- mice and WT mice (neutrophils: 5.5 –
0.4 vs. 4.4 – 0.6; macrophages: 0.5 – 0.2 vs. 0.8 – 0.1; CD4+
T cells: 0.9 – 0.1 vs. 0.6 – 0.2; and CD8+ T cells: 0.8 – 0.2 vs.
0.6 – 0.2, expressed as number of cells/field in n = 6 mice/
group), which ruled out the possibility that an immune or
inflammatory reaction caused the cardiac changes in Sirt3-/-
mice. Cardiac abnormalities in these animals were not associ-
ated with changes in lipid plasma levels or renal function im-
pairment in terms of proteinuria (Supplementary Table S1).
FIG. 1. Sirt3-/- mice have reduced life span. Kaplan–
Meier survival curves for male WT (right censored) and
Sirt3-/- mice. The p-value was derived from log-rank cal-
culations, n = 25 mice/group. p-value of <0.0001 versusWT.
SIRT3, sirtuin 3; WT, wild type.
Innovation
Sirtuin 3 (Sirt3) deficiency is associated with several
diseases of aging, but whether the sequelae of Sirt3 defi-
ciency translated into an effect on life span is unknown.
We show that Sirt3-/- mice have shortened life span with
cardiac abnormalities that include altered mitochondrial
bioenergetics and hyperacetylation of optic atrophy 1
(OPA1), associated with aberrant alignment of trans-
mitochondrial cristae in cardiomyocytes, and cardiac
dysfunction. Given our finding that the correction of
cardiac OPA1 hyperacetylation through gene transfer re-
stored trans-mitochondrial cristae alignment and limited
heart failure in aged Sirt3-/- mice, we envision future
approaches to heart failure, including SIRT3 as a plausi-
ble therapeutic target.
1256 BENIGNI ET AL.
As for the other organs, mild renal interstitial fibrosis de-
veloped in Sirt3-/-mice comparable withWTmice, as shown
by stainings of the kidney tissue for collagen I and III fibers
(Sirius Red, Supplementary Fig. S1) or for alpha-smooth
muscle actin (a-SMA, Supplementary Fig. S1). However,
these abnormalities did not translate into a pathological renal
phenotype (Supplementary Table S1). As for the liver, we
found modest abnormalities that did not translate into full-
blown liver dysfunction, as demonstrated by normal levels of
plasma alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) levels (Supplementary Table S1). No
histological alterations were found in the brain, nor was an
increased incidence of tumors observed in Sirt3-/- mice
compared with WT mice.
Sirt3 deficiency compromises mitochondrial
connectivity and communication in the heart
The absolute mass of cardiac mitochondria was signifi-
cantly reduced in Sirt3-/- compared with WT mice, which
was demonstrated in the analysis of citrate synthase activity
(Fig. 3A). In addition to mass reduction, the ATP synthesis
rate was also reduced in Sirt3-/- hearts compared with those
of WT mice, reflecting low energy production in the former
group (Fig. 3B).
Next, we wanted to understand why the energetic state of
Sirt3-/-mice was compromised. We thus turned our attention
to mitochondrial connectivity and communication, a crucial
factor in cellular homeostasis (21). We investigated the
structural integrity of the mitochondrial network in Sirt3-/-
and WT mice using transmission electron microscopy at a
nanometer resolution range.
We found that Sirt3 deficiency affected trans-mitochondrial
cristae coordination to a significant extent. Specifically, we
observed an aberrant alignment of trans-mitochondrial cristae
in most mitochondria in the hearts of mice lacking Sirt3,
compared with age-matched WT mice (Fig. 3C). Mitochon-
drial cristae architecture, although not completely disrupted,
was predominantly abnormal in Sirt3-/- mice compared with
the regular cristae distribution in WT mice (Fig. 3C). Speci-
fically, mitochondrial cristae were rarely organized as parallel
stacks, as is usually observed in WT animals (Fig. 3C).
Effect of Opa1 gene transfer on mitochondrial structure
and function
There is evidence that SIRT3 regulates mitochondrial
function and dynamics through the deacetylation and acti-
vation of optic atrophy 1 (OPA1), a pro-fusion protein of the
inner mitochondrial membrane (31, 41). In this study, we
wondered whether the lack of trans-mitochondrial cristae
coordination in our model was caused by Sirt3 deficiency and
the consequent hyperacetylation of OPA1. Total OPA1 was
evaluated in isolated mitochondria of cardiac tissue by
Western blot analysis. We found that total OPA1 was sig-
nificantly reduced in Sirt3-/- compared with WT mice
(Fig. 3D), and it was hyperacetylated (Fig. 3D).
We then investigated whether the impaired trans-
mitochondrial cristae alignment found in Sirt3-/- mice could
be corrected by inducing the expression of the deacetylated
and active mutant (mut) form of OPA1. To this end, we
generated an adeno-associated virus serotype 9 (AAV9)-
mutOpa1-vector encoding for a deacetylation-mimetic version
of murine OPA1, in which two conserved lysines, K944 and
K949, were replacedwith two arginins (R) tomimic the function
of SIRT3. AAV9was chosen for its uniquely exuberant cardiac
tropism (55). An AAV9-LacZ vector served as a control.
Cardiomyocytes were efficiently transduced after the in-
jection of 1.3 · 1012 viral genome/animal of AAV9-LacZ
(Supplementary Fig. S2). Western blot analysis of mito-
chondrial extracts revealed that gene transfer of mutOpa1
increased total OPA1 protein levels, as expected, and effec-
tively reduced the quantity of acetylated OPA1 in Sirt3-/-
hearts (Fig. 4A). Two weeks after injection, the expression of
the SIRT3-insensitive version of OPA1 did not have an im-
pact on cardiac mitochondrial mass (citrate synthase activity,
lmole/mL/min: 0.014 – 0.003 in Sirt3-/- mice injected with
FIG. 2. Sirt3-/- mice exhibit cardiac
abnormalities. (A) Quantification of HW
and BW ratio (HW/BW) in aged WT and
Sirt3-/- mice (20–35.5 months of age,
n = 8/group). (B) Collagen deposition in
the hearts of aged mice (20–35.5 months
of age, n = 8/group). (C) Representative
images of collagen deposition assessed
by Sirius Red staining in cardiac tissue
harvested from aged WT and Sirt3-/-
mice. Scale bars: 20lm. Values are
mean–SEM. The p-values were derived
from unpaired Student’s t-test. **p< 0.01;
*p< 0.05. BW, body weight; HW, heart
weight; SEM, standard error of the mean.
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AAV9-LacZ vs. 0.013 – 0.002 in Sirt3-/- mice injected with
AAV9-mutOpa1, n=4 mice/group), but improved cardiac ATP
content in Sirt3-deficient mice (Fig. 4B). Strikingly, mutOpa1
gene delivery restored the proper alignment of the cristae of
adjacent mitochondria (Fig. 4C, D). Transfection withmutOpa1
also effectively reduced cardiac hypertrophy (Fig. 4E).
To confirm that the protective effect of gene transfer on
cardiac abnormalities was fully dependent on OPA1’s dea-
cetylated status rather than on its expression levels, we per-
formed gene transfer experiments of WT Opa1 (wtOpa1) in
Sirt3-/-mice. Total OPA1 protein levels increased after gene
delivery (Fig. 4F). Under Sirt3-deficient conditions, wtOpa1
could not be deacetylated as revealed by comparable levels of
hyperacetylated OPA1 in mice injected with AAV9-wtOpa1
and AAV9-LacZ (Fig. 4F). Likewise, the transduction of
wtOpa1 did not improve cardiac mitochondrial mass (citrate
synthase activity, lmole/mL/min: 0.016– 0.001 in Sirt3-/-
mice injected with AAV9-LacZ vs. 0.015– 0.001 in Sirt3-/-
mice injected with AAV9-wtOpa1, n = 4 mice/group), or
ATP content (Fig. 4G). Unlike mutOpa1, wtOpa1 did not
promote trans-mitochondrial cristae alignment (Fig. 4C, D),
nor did it limit cardiac hypertrophy (Fig. 4E).
Effect of Opa1 gene transfer on cardiac dysfunction
in the long term
Next, we investigated whether the effects that the gene
transfer of the mutOpa1 had on mitochondrial structure and
FIG. 3. Alterations in mi-
tochondrial bioenergetics,
trans-mitochondrial cristae
alignment, and OPA1 acet-
ylation in cardiac tissue of
Sirt3-/- mice. (A) Levels of
citrate synthase activity, and
(B) ATP content in total
cardiac extracts of WT and
Sirt3-/- mice (n = 4/group).
(C) Representative transmis-
sion electron micrographs
and percentage of mitochon-
dria with aligned trans-
mitochondrial cristae in WT
and Sirt3-/- mice (n = 3/
group). Scale bar: 1 lm. In-
sets: schematic drawing of
trans-mitochondrial coordi-







Western blot of acetylated
(ac-OPA1) and total OPA1
in mitochondrial cardiac
extracts from WT and
Sirt3-/- mice (n = 4/group).
VDAC was used as sample-
loading controls in isolated
mitochondria. WT and
Sirt3-/- mice were analyzed
at 15 months of age. Values
are mean – SEM. For (A, B,
D), the p-values were de-
rived from unpaired Stu-
dent’s t-test. For (C), the
p-value was derived from
GENMODprocedure in SAS.
***p < 0.001; **p < 0.01;
*p <0.05. OPA1, optic atro-
phy 1; VDAC, voltage-
dependent anion channel.
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function, observed earlier, translated into end-organ cardiac
protection.
To determine the optimal timing for therapeutic inter-
vention, we first evaluated a-SMA expression and collagen I
deposition as markers of fibrosis in the cardiac tissue of
Sirt3-/- mice (Supplementary Fig. S3A). a-SMA expression
was already higher in Sirt3-/- mice compared with WT
mice at 15 months (% of positive cells/field: 6.78 – 0.29 vs.
3.60 – 0.96, p-value of <0.05, n = 3 mice/group) and rose
further at 20 months (15.27– 3.53 vs. 3.62 – 0.19, p-value of
<0.05, n = 3 mice/group) (Supplementary Fig. S3A). Col-
lagen I deposition was similar in Sirt3-/- and WT mice at 15
months (score: 0.20 – 0.03 vs. 0.17 – 0.02, n = 3 mice/group),
but rose significantly higher at 20 months in Sirt3-/- mice
than in WT mice (0.56 – 0.05 vs. 0.23 – 0.03, p-value of
<0.01, n = 3 mice/group) (Supplementary Fig. S3B). Based
on a-SMA and collagen I expression in cardiac tissue, Sirt3-/-
mice at 18–20 months of age were treated with AAV9-mu-
tOpa1 or AAV9-LacZ and sacrificed after 3 months. The
gene transfer approach proved capable of preserving in the
long term an effective state of OPA1 deacetylation in Sirt3-/-
mice (Fig. 5A).
Since respiratory chain complexes are key structures for
mitochondrial bioenergetics and reside on the cristae mem-
brane, we evaluated the activity of the gatekeeper of the re-
spiratory chain, Complex I, the formation and stabilization
of which are dependent on OPA1. The activity of im-
munocaptured Complex I from cardiac tissue lysates was
analyzed based on oxidation of NADH to NAD+, and found
to be remarkably lower in Sirt3-/- mice receiving AAV9-
LacZ vector compared with WT mice (Fig. 5B). MutOpa1
transduction restored the Complex I activity to levels that
were indistinguishable from those ofWTmice (Fig. 5B). As a
consequence, NAD+ levels, which were reduced in AAV9-
LacZ Sirt3-/- mice, were normalized after mutOpa1 over-
expression (Fig. 5C).
The reduced respiratory capacity of AAV9-LacZ Sirt3-/-
mice yielded lower ATP production, which was replenished
to control levels by mutOpa1 (Fig. 5D). The improvement in
mitochondrial bioenergetics by mutOpa1 was accompanied
by an increase in mitochondrial mass, evaluated as citrate
synthase activity (Fig. 5E).
Long-term transduction withmutOpa1 led to a reduction in
hypertrophy and the heart-to-body weight ratio was nor-
malized (Fig. 6A). The protective effect of mutOpa1 on
cardiac hypertrophy was accompanied by reduced fibro-
sis, assessed through both a-SMA (Fig. 6B) and collagen I
(Fig. 6C) immunostainings.
We then measured global left ventricular function using
echocardiography at rest and during a low-dose dobutamine
(LDD) stress test to evaluate myocardial viability and con-
tractile performance in response to an acute increase in
workload (48). LDD stress echocardiography was tolerated
well in all animals and we did not encounter any complica-
tions. The dobutamine was effective at a low dose, as dem-
onstrated by a statistically significant increase in left ventricle
fractional shortening (LVFS), under stress, compared with
baseline in WT mice (Fig. 6D). In Sirt3-/- mice receiving
AAV9-LacZ vector, the LDD stress test did not increase the
inotropic cardiac reserve, which instead increased signifi-
cantly in Sirt3-/- mice transduced with mutOpa1 (Fig. 6D).
There was no difference in chronotropic response to LDD
between groups (AAV9-LacZ: pre 515.0 – 34.1 beats per
minute (bpm) vs. post 474.3– 34.7 bpm; AAV9-mutOpa1: pre
449.8– 8.8 bpm vs. post 459.0– 5.9 bpm; WT: pre 474.4–
40.3 bpm vs. post 536.6– 60.9 bpm). This is not surprising,
since others have found that LDD did not induce changes in
heart rate (8). All the above findings suggest a link between
the replacement of trans-mitochondrial cristae alignment and
recovery of cardiac structure and function.
That the effect of gene transfer actually depended on
OPA1 deacetylation was supported by findings that hyper-
acetylation of total mitochondrial proteins, including the
SIRT3 target superoxide dismutase 2 (SOD2), in Sirt3-/-
mice (Supplementary Fig. S4A) was not affected bymutOpa1
gene delivery (Supplementary Fig. S4B).
SIRT3 silencing alters mitochondrial morphology
and contractile behavior in human iPSC-derived
cardiomyocytes
Having established that there is a strong correlation be-
tween SIRT3 and cardiac function in mice, we sought to
investigate the effect of SIRT3 deficiency on spontaneously
beating human iPSC-derived cardiomyocytes. To this end,
human iPSC-derived cardiomyocytes were silenced for the
SIRT3 gene through a specific small interfering RNA (siR-
NA). SIRT3 silencing resulted in 85% inhibition of SIRT3
mRNA expression, compared with cells transfected with
small interfering RNA null (siNULL) (Fig. 7A).
In this setting, we investigated the effect of SIRT3 dele-
tion on mitochondrial structural integrity by using an image
preprocessing tool to quantitatively capture morphological
changes in the mitochondrial network (50). Using Mito-
Tracker staining, we found that almost the 60% of siNULL
iPSC-derived cardiomyocytes exhibited a subset of highly
packed and round mitochondria near the perinuclear region,
while highly packed mitochondria were found in only 20%
of SIRT3-deficient iPSC-derived cardiomyocytes (Fig. 7B).
In addition, iPSC-derived cardiomyocytes exhibited a
highly interconnected mitochondrial network, which extends
through the whole cytoplasmic compartment of the cells
following siNULL transfection (Fig. 7C). The deletion of
SIRT3 markedly altered the overall structural architecture of
the mitochondrial lattice in iPSC-derived cardiomyocytes, to
the extent that the mitochondrial networks and area were
significantly reduced compared with their SIRT3-competent
counterpart (Fig. 7C). In-depth analysis revealed that the
reduced mitochondrial network, which followed SIRT3 si-
lencing, was the consequence of the specific loss of both
mitochondrial branches (siNULL: 551 – 29 vs. small in-
terfering RNA for sirtuin 3 [siSIRT3]: 371– 20 number/cell,
p-value of <0.01) and junctions (siNULL: 186 – 9 vs. si-
SIRT3: 129 – 8 number/cell, p-value of <0.01), as described
by Valente et al. (50).
An extensive body of evidence has shown that both the
shape and positioning of mitochondria tightly controls Ca2+-
handling of cardiomyocytes (47). To investigate the mecha-
nisms underlying the observed altered beating contraction,
we analyzed the Ca2+-handling properties of iPSC-derived
cardiomyocytes by using the Ca2+ fluorescent dye FLUO-4.
The live-imaging recording showed that after siNULL
transfection, high-intensity Ca2+ sparks emerged synchro-
nously in both the nuclear and cytoplasmic regions of the
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iPSC-derived cardiomyocytes (Supplementary Movie S1). In
contrast, SIRT3 silencing translated into irregular Ca2+ re-
lease that was not synchronized among iPSC-derived cardi-
omyocytes of a monolayer, without apparent changes in
either intensity or duration of Ca2+ sparks (Supplementary
Movie S2).
We subsequently examined how SIRT3 silencing affected
cardiomyocyte contraction. Through Cell Observer analysis,
phase-contrast monitoring of living human iPSC-derived
cardiomyocytes treated with siNULL revealed a regular,
autonomous beating rate with a frequency that remained al-
most constant during the temporal course of the measure-
ments (Supplementary Movie S3). In the face of reduced
SIRT3 expression, iPSC-derived cardiomyocytes exhibited
uncontrolled spontaneous beating that led to the generation of
ectopic foci of contraction (Supplementary Movie S4).
To evaluate whether the dysfunctioned phenotype of car-
diomyocytes could be rescued by restoring functional OPA1,
we transduced mutOpa1 in SIRT3-silenced iPSC-derived
cardiomyocytes. First, we found that SIRT3-silenced iPSC-
derived cardiomyocytes exhibited downregulation of OPA1
and increased protein acetylation compared with siNULL-
transfected cells (Fig. 7D, E). By contrast, mutOpa1 gene
transfer effectively increased total OPA1 protein expression
and reduced its acetylation levels (Fig. 7D, E). To investigate
whether the restoration of functional OPA1 translated into an
amelioration of cardiomyocyte function, we assessed human
iPSC-derived cardiomyocyte contraction. Cardiomyocytes
transfected with siNULL and LacZ exhibited a regular, au-
tonomous beating rate (Supplementary Movie S5), while
SIRT3-silenced cardiomyocytes transfected with LacZ
showed uncontrolled spontaneous beating (Supplementary
Movie S6). Remarkably, transfection of mutOpa1 restored
the spontaneous synchronous beating of SIRT3-silenced
cardiomyocytes (Supplementary Movie S7).
To provide further functional data on mitochondrial ac-
tivity in cardiomyocytes transfected with mutOpa1, we
evaluated the expression of ATP synthase subunit e (ATP5I)
that is required for ATP synthase dimerization and proper
functioning (38). As shown in Figure 7D and F, we found that
SIRT3 silencing in iPSC-derived cardiomyocytes signifi-
cantly reduced ATP5I protein expression compared with
siNULL-transfected cells. Levels of ATP5I protein were
even higher than in siNULL-transfected cells by mutOpa1
gene transfer (Fig. 7D, F).
Discussion
In this study, we report for the first time that SIRT3 has a
major role in regulating life span in mice. The limited sur-
vival time of Sirt3-/- animals is associated with severe heart
structure damage and dysfunction. Heart damage parallels
defective trans-mitochondrial cristae alignment and impaired
bioenergetics, which are linked to suboptimal OPA1 deace-
tylation. The salient feature of the present study is the utili-
zation of a targeted gene transfer involving mutOpa1 that
reverses heart failure. Silencing SIRT3 in human iPSC-
derived cardiomyocytes disrupts mitochondrial integrity and
alters cell contractility, rescued by mutOpa1 gene delivery.
The first novel finding of this study is that Sirt3 deficiency
shortens life span inmice. To the best of our knowledge, there
are no other studies that document the effect of a specific
mitochondrial SIRT on survival in mammals. A study that
has been recently published (53) is worth mentioning here. In
Drosophila melanogaster, life span is shortened by knock-
down of Sirt4, encoding the sole predicted mitochondrial
SIRT in this model organism, while flies overexpressing Sirt4
ubiquitously or in the fat body are long-lived. It is noteworthy
that several phenotypes of Sirt4 knockout fruit fly are remi-
niscent of those found here in Sirt3-/-mice. As the authors of
the above article have indicated, it is possible that Sirt4 in the
fruit fly could be a counterpart of the mammalian SIRT3.
In this study, we have demonstrated that Sirt3-deficient
animals primarily experience signs of severe cardiomyopathy
as they age. While this finding may not be entirely new (15,
45), it is worth mentioning here that Sirt3-/- mice were fol-
lowed up for a long period of time, long enough to demon-
strate differences in heart pathologies, including hypertrophy
and fibrosis. In the long run, these changes were associated
with signs of heart failure.
As the main mitochondrial SIRT, SIRT3 deacetylates
many proteins in the organelles and promotes diverse aspects
of health span, but the role of SIRT3 goes beyond deacety-
lating specific mitochondrial substrates. It also regulates
mitochondrial function at many other levels (26). Given that
cardiac tissue has the highest number of mitochondria and the
‰
FIG. 4. Effect of mutOpa1 and wtOpa1 gene transfer on OPA1 acetylation, mitochondrial bioenergetics, trans-
mitochondrial cristae alignment, and cardiac hypertrophy in Sirt3-/- mice. (A) Representative gels and densitometric
analysis of Western blot of acetylated (ac-OPA1) and total OPA1 in mitochondrial cardiac extracts of Sirt3-/- mice injected
with AAV9-LacZ (LacZ) or AAV9-mutOpa1 (mutOpa1) (n = 4/group). VDAC was used as sample-loading controls in
isolated mitochondria. (B) Levels of ATP content in total cardiac extracts of Sirt3-/- mice injected with LacZ or mutOpa1
(n= 4/group). (C) Representative transmission electron micrographs and (D) percentage of mitochondria with aligned trans-
mitochondrial cristae in Sirt3-/- mice injected with LacZ, mutOpa1, or wtOpa1 (n = 3/group). Scale bar: 1lm. Insets:
schematic drawing of trans-mitochondrial coordination of cristae.White arrows indicate adjacent mitochondria with aligned
trans-mitochondrial cristae. (E) Quantification of cardiac hypertrophy in WT and Sirt3-/- mice injected with LacZ, mu-
tOpa1, or wtOpa1 (n = 4/group). (F) Representative gels and densitometric analysis of Western blot of acetylated (ac-OPA1)
and total OPA1 in mitochondrial cardiac extracts of Sirt3-/- mice injected with LacZ (n = 4/group) or AAV9-wtOpa1
(wtOpa1) (n= 3/group). VDAC was used as sample-loading controls in isolated mitochondria. (G) Levels of ATP content in
total cardiac extracts of Sirt3-/- mice injected with LacZ or wtOpa1 (n= 4/group). Gene transfer experiments were per-
formed in Sirt3-/- mice at 15 months of age, and the analyses were performed 2 weeks after AAV9 injection. Values are
mean– SEM. For (A, B and F, G), the p-values were derived from unpaired Student’s t-test. For (D), the p-value was
derived from GENMOD procedure in SAS. For (E), the p-values were derived from ANOVA with Tukey post hoc test.
***p< 0.001; **p< 0.01; *p< 0.05. AAV9, adeno-associated virus serotype 9; ANOVA, analysis of variance.
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highest levels of oxygen consumption of all organs, Sirt3
deletion primarily affects the heart. Indeed, Sirt3-/- mice
exhibited abnormal cardiac mitochondrial clustering and re-
duced mass associated with a lower than normal ATP syn-
thesis rate, which would suggest an altered bioenergetic state.
Actually, bioenergetics in mitochondria depends on the
reciprocal connectivity, which is guaranteed by specific
junctions acting as unique electrochemical systems (3, 7, 36).
While we confirmed the elegant findings of Picard et al.,
which found that adjacent mitochondria finely coordinate the
curvature of their cristae with each other (37), we also found
that in Sirt3-/-mice, this parallel alignment with the cristae of
neighboring mitochondria was lost. This could explain the
compromised mitochondrial energetics in Sirt3-deficient
animals in the present study. To date, no other instance of
aberrant trans-mitochondrial cristae alignment in a disease
model has been reported. It is tempting to speculate that
shortened life span and heart abnormalities could indeed be
direct consequences of abnormal intermitochondrial inter-
action.
Since mitochondrial dysfunction in the hypertrophic heart
is dependent on the state of deacetylation of OPA1 (41), we
chose to investigate whether the lack of coordination of mi-
tochondrial cristae was due to suboptimal OPA1 deacetyla-
tion of Sirt3-/- animals. Gene transfer experiments with
constitutively deacetylated mutOpa1 fully reconstituted mi-
tochondrial cristae coordination with the appropriate curva-
ture within mitochondria in Sirt3-/- mice. This unique
property of OPA1 has never been reported before, to the best
of our knowledge.
We also found that the restoration of mitochondrial
connectivity translated functionally into recovery of ATP
content, which can be taken as an indication of restored mi-
tochondrial bioenergetics. The possible role that mutOpa1
FIG. 5. Long-term effect
of mutOpa1 gene transfer
on mitochondrial function
in Sirt3-/- mice. (A) Re-
presentative gels and densi-
tometric analysis of Western
blot of acetylated (ac-OPA1)
and total OPA1 in mito-
chondrial cardiac extracts of
WT mice, and Sirt3-/- mice
injected with LacZ or mutO-
pa1 (n= 6/group). VDAC
was used as sample-loading
controls in isolated mito-
chondria. (B–E) Evaluation
of Complex I enzymatic ac-
tivity (B) expressed as milli
optical density per min
(mOD/min), NAD+ levels
(C), ATP content (D), and
citrate synthase activity (E)
in cardiac extracts of WT
mice, and Sirt3-/- mice in-
jected with LacZ or mutOpa1
(n= 6/group). Gene transfer
experiments were performed
in Sirt3-/- mice at 18–20
months of age, and the ana-
lyses were performed 3
months after AAV9 injec-
tion. WT age-matched mice
were studied as controls.
Values are mean– SEM. The
p-values were derived from
ANOVA with Tukey post
hoc test, ***p < 0.001;
**p< 0.01; and *p < 0.05.
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FIG. 6. Long-term effect of mutOpa1 gene transfer on cardiac structure and function in Sirt3-/- mice. (A) HW and
BW ratio (HW/BW) in WT mice (n = 5/group), and Sirt3-/- mice injected with LacZ (n= 4/group) or mutOpa1 (n= 4/group).
(B) Representative images of a-SMA (red) expression in cardiac tissue by immunofluorescence analysis in WT, LacZ, and
mutOpa1 mice. Cardiac structures and nuclei are counterstained with fluorescein isothiocyanate-WGA (green) and DAPI
(blue), respectively. Scale bars: 50lm. (C) Representative images of collagen I (red) deposition from immunofluorescence
analysis in cardiac tissue of WT, LacZ, and mutOpa1 mice. Cardiac nuclei are counterstained with DAPI (blue). Scale bars:
50 lm. (D) Assessment of LVFS (LVFS%) by echocardiography before (Pre) and after (Post) dobutamine stress in WT mice
(n = 5/group), and Sirt3-/- mice injected with LacZ (n = 4/group) and mutOpa1 (n = 4/group). Transfection experiments were
performed in Sirt3-/- mice at 18–20 months of age, and the analyses were performed 3 months after AAV9 injection. WT
age-matched mice were studied as controls. Values are mean – SEM. For (A), the p-values were derived from ANOVA with
Tukey post hoc test. For (D), the p-values were derived from paired Student’s t-test. ***p < 0.001; *p < 0.05. a-SMA, alpha-
smooth muscle actin; DAPI, 4¢,6-diamidino-2-phenylindole; LVFS, left ventricle fractional shortening; WGA, wheat germ
agglutinin.
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FIG. 7. Effect ofmutOpa1 gene transfer in SIRT3 silenced human pluripotent stem cell-derived cardiomyocytes. (A)
Evaluation of SIRT3 mRNA levels in human iPSC-derived cardiomyocytes transfected with a control nontarget small
interfering (siNULL) or specific for human SIRT3 (siSIRT3). [(B), left panel] Representative images of mitochondrial
distribution visualized by MitoTracker staining (red) in human iPSC-derived cardiomyocytes transfected with siNULL or
siSIRT3. Nuclei are counterstained with Hoechst (blue). Scale bar 20 lm. [(B), right panel] Quantification of mitochondrial
perinuclear distribution in iPSC-derived cardiomyocytes transfected with siNULL or siSIRT3 (n = 3 independent experi-
ments). (C) Quantification of mitochondrial network and area in iPSC-derived cardiomyocytes transfected with siNULL or
siSIRT3 by the Mitochondrial Network Analysis toolset (n = 3 independent experiments). Images in (C) are obtained after
skeletonization by Fiji software of representative images in (B). n = nuclei. (D–F) Representative gels (D) and densitometric
analysis of Western blot of total OPA1 and acetylated (E), and ATP5I (F) in total extracts of siNULL iPSC-derived
cardiomyocytes transfected with LacZ and of siSIRT3-silenced iPSC-derived cardiomyocytes transfected with LacZ or
mutOpa1 (n = 3 independent experiments). VDAC was used as sample-loading controls. Values are mean – SEM. For (A–
C), the p-values were derived from unpaired Student’s t-test. For (D, E), the p-values were derived from ANOVA with
Tukey post hoc test. ***p < 0.001; **p< 0.01; and *p < 0.05. ATP5I, ATP synthase subunit e; iPSC, induced pluripotent
stem cell; siNULL, small interfering RNA null; siSIRT3, small interfering RNA for sirtuin 3.
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has in restoring energy production in Sirt3-/- mice could be
due to the capability of OPA1 to maintain cristae shape, a
prerequisite for the assembly and stability of respiratory
chain supercomplexes and hence mitochondrial respiratory
efficiency (11). Finding that gene transfer of wtOpa1 did not
affect mitochondrial structure and function, further corrobo-
rated the hypothesis that SIRT3 has a critical role in activating
OPA1. SIRT3-dependent deacetylation of OPA1 is the only
reported posttranslational modification known to promote the
activity of OPA1. Our data therefore provide unique proof of
principle that modulating the expression of a single gene can
have a profound influence on reduced organelle efficiency in
Sirt3-/- mice. The finding that the correction of OPA1 hy-
peracetylation via gene transfer sufficed to limit the abnormal
myocyte size of Sirt3-/-mice 2weeks aftermutOpa1 injection
was already an indication that this maneuvre could theoreti-
cally preserve cardiac dysfunction.
The next step was to explore the potential ofmutOpa1 gene
delivery to mitigate accelerated cardiac hypertrophy, which
develops in Sirt3-/- mice with age. To actually determine
whether this was the case, we performed two sets of experi-
ments based on echocardiography and LDD stress to assess
cardiac inotropic reserve (48), given that there is evidence
that cardiac inotropic response is a function of mitochondrial
integrity and energy production (40). While global systolic
function in Sirt3-/- andWTmice under resting conditions was
the same, the dobutamine challenge unmasked an insufficient
contractile response that can reasonably be attributed to the
impairment of mitochondrial energetics production in Sirt3-/-
mice. Indeed, we found that Sirt3-/- mice exhibited reduced
Complex I activity in the mitochondrial electron trans-
port chain, with a consequent decrease in NAD+ and ATP
generation.
These findings may underlie the close link between the
SIRT3-dependent OPA1 deacetylation and the preserved
spatial distribution of cristae membranes. There is evidence
showing that improvement of mitochondrial cristae shape
induced by OPA1 ameliorates mitochondrial energetic effi-
ciency (51), as it occurs here with the restoration of Complex
I activity after mutOpa1 gene transfer. This interpretation
was confirmed by the finding that these abnormalities were
completely overturned by long-term mutOpa1 gene trans-
fer experiments, which also restored the inotropic response
of the heart. It is worth mentioning that deacetylation of
OPA1—but not of other mitochondrial proteins including
SOD2—maintained in the long term in Sirt3-/- animals,
corrected cardiac dysfunction and fibrosis, demonstrating this
maneuvre’s previously unanticipated potential for cardiac
protection. Studies have shown that mitochondrial dysfunc-
tion in cardiomyocytes critically contributes to the development
of age-associated cardiac fibrosis by impairing bioenergetics
and reducing cell survival (1, 28, 49). Furthermore, based on the
recent evidence that Complex I inhibition is sufficient to pro-
mote the development of fibrosis in the lung, it is tempting to
infer that the normalization of Complex I activity through
mutOpa1 gene transfer contributes to the amelioration of
cardiac fibrosis (30).
In search of a potential proof-of-concept that SIRT3 defi-
ciency induced cardiomyocyte dysfunction in human speci-
mens as it occurred in mice lacking Sirt3, we sought to study
human iPSC-derived cardiomyocytes and used these cells
to abrogate SIRT3 expression via specific siRNA. SIRT3
silencing led to altered mitochondrial morphology by reducing
the subset of perinuclear mitochondria in iPSC-derived car-
diomyocytes. This is significant, given that this mitochon-
drial clustering is an important factor in ATP generation and
the formation of direct energetic channeling between mito-
chondria and the nucleus (9, 13, 22), possibly explaining the
energetic defect observed in Sirt3-/- mice.
On the contrary, SIRT3 also affected the overall cyto-
plasmic mitochondrial network, which contributes to Ca2+-
handling and sustains the proper cardiac contraction (12). In
this context, our findings revealed impairment in the iPSC-
derived cardiomyocyte contractile phenotype associated with
altered Ca2+ signaling in the face of reduced SIRT3 expres-
sion. We know that human iPSC-derived cardiomyocytes
may exhibit several limitations mainly due to their immature
phenotype compared with adult cardiomyocytes. However,
the novel finding of the present study is that SIRT3 silencing
impairs cardiomyocyte contraction and that this phenomenon
is fully rescued by restoring OPA1 activity. It is conceivable
that our present results explain recent evidence that DNA se-
quence variants, which actually decrease SIRT3 transcription,
play a role in promoting myocardial infarction in humans (54).
Given the theoretical potential for targeting SIRT3 path-
ways for healthy aging and cardiovascular fitness, this study
provides an interesting opportunity to look at gene transfer
technology as a therapeutic strategy for the clinical arena in
addition to present pharmaceutical treatments. A gene mod-
ifying strategy targeting SIRT3 should be especially wel-
come, in view of the fact that attempts at identifying a specific
SIRT3 activator have repeatedly failed.
Materials and Methods
Animal studies
Sirt3-/- mice generated in a mixed genetic background
(provided by Professor Frederick W. Alt, Harvard Medical
School, Boston, MA) (25) and their C57BL/6x129 WT lit-
termates were used. Mice were maintained in a specific
pathogen-free facility with a 12-h dark/12-h light cycle, in a
constant temperature room with free access to standard diet
and water. Only male mice were used. Animals were fol-
lowed up throughout their life span (n = 25 for each group).
Mice were sacrificed when death appeared imminent, and
heart, kidneys, liver, and brain were harvested for tissue
analysis. Tumor incidence was determined through histo-
pathological examination of hematoxylin- and eosin-stained
slides from the heart, liver, brain and aorta. The oldest WT
mice (4/25) were sacrificed at 35.5 months of age for organ
collection. Additional WT and Sirt3-/- mice were sacrificed
at 15 months of age for analysis in cardiac tissues. AAV9-
LacZ, AAV9-mutOpa1, and AAV9-wtOpa1 gene delivery
experiments were performed in Sirt3-/-mice at 15 months of
age (n = 3/group), and mice sacrificed 2 weeks after AAV9
injection for cardiac analysis. Additional AAV9-LacZ and
AAV9-mutOpa1 gene delivery experiments were performed
in Sirt3-/- mice at 18–20 months (n= 4/group), and mice
were sacrificed 3 months after AAV9 injection for cardiac
analysis. WT age-matched mice were studied as controls.
All procedures involving animals were performed in ac-
cordance with institutional guidelines in compliance with
national (D.L.n.26, March 4, 2014) and international laws
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and policies (Directive 2010/63/EU on the protection of an-
imals used for scientific purposes).
Laboratory parameters
Plasma levels of cholesterol, triglycerides, ALT, and AST
were measured by the Reflotron test (Roche Diagnostic Cor-
poration, Indianapolis). Urinary protein excretion was mea-
sured through the Comassie method using Cobas Mira
autoanalyzer (RocheDiagnostics Systems, Risch, Switzerland).
Cardiac tissue analysis
Cardiomyocyte cross-sectional areas were evaluated on
light microscopy images at· 400 magnification, from at least
50 cells in each group, and measured by manually tracing the
cell contour using the ImageJ analysis program (ImageJ 1.42q)
(4). Cardiac tissues were formalin fixed, paraffin embedded,
and sectioned at 5lm for hematoxylin/eosin and at 10lm for
collagen staining (0.1% Sirius Red in picric acid). Collagen
content was quantified in digitally acquired images. The nature
of Sirius Red-stained collagen deposits was confirmed by ex-
amination under a microscope equipped with polarized light
that renders collagen fibers birefringent.
a-SMA and collagen I expression was evaluated through
immunofluorescence analysis. Frozen heart sections (3lm)
were fixed with cold acetone and incubated with 1% bovine
serum albumin (BSA) to block nonspecific sites. Sections
were then incubated with cy3-conjugated mouse anti-a-SMA
(clone 1A4; Sigma-Aldrich, St. Louis, MO) or rabbit anti-
collagen I (ab34710; Abcam, Cambridge, United Kingdom),
the latter followed by Cy3-conjugated goat anti-rabbit im-
munoglobulinG (IgG, 111-165-144; Jackson Immunoresearch
Laboratories, West Grove, PA). Nuclei were stained with 4¢,6-
diamidino-2-phenylindole, while fibrotic tissue was labeled
with fluorescein isothiocyanate wheat germ agglutinin (Vector
Laboratories, Burlingame, CA). The expression of a-SMAwas
quantified as percentage of positive cardiomyocytes, and col-
lagen I signal was graded on a scale of 0–3 (0: no signal, 1:
weak, 2: mild, 3: diffuse), in at least 10–15 randomly selected
high-power fields for each animal.
Immunofluorescence analysis of leukocytes
in cardiac tissues
Intragraft leukocytes were analyzed in situ using an indi-
rect immunofluorescence technique on frozen tissue sections
(3 lm). The sections were incubated with the following an-
tibodies: rat anti-mouse granulocytes (Gr-1, clone RB6-8C5;
Biolegend, San Diego, CA) or rat anti-mouse F4/80 (clone
BM8; Invitrogen, Carlsbad, CA) for macrophages, both fol-
lowed by Cy3-conjugated goat anti-rat IgG (112-166-062;
Jackson Immunoresearch Laboratories); rat anti-mouse CD4
(clone RM4–5; Biolegend); or rat anti-mouse CD8a (clone
53-6.7; BioLegend) both followed by AF488-conjugated
goat anti-rat IgG (A-11006; Invitrogen). For each marker, the
number of total positive cells was counted in at least 15–20
randomly selected high-power fields for each animal.
Transmission electron microscopy
Immediately after excision, cardiac tissue samples were
fixed with 2.5% glutaraldehyde in 0.1M cacodylate buffer
(pH 7.4) overnight at 4C and postfixed in 1% osmium te-
troxide for 1 h. Then, specimens were dehydrated through
ascending grades of alcohol and embedded in Epon resin.
Semithin sections (1 lm) were stained with toluidine blue in
borax and examined by light microscopy. Ultrathin sections
(60–100 nm) were cut on an ultramicrotome (LKB Instru-
ments, Milan, Italy), collected on copper grids, and stained
with uranyl acetate and lead citrate. The morphological
analysis of ultrastructure was performed using transmission
electron microscopy (Morgagni 268D; Philips, Brno, Czech
Republic). In total, at least 100 pairs of adjacent mitochondria
were analyzed for WT and Sirt3-/- mice, and mitochondria
showing coordination of cristae were counted. In Sirt3-/-
mice injected with AAV9-mutOpa1, or AAV9-wtOpa1, a
total of 288 pairs of adjacent mitochondria were studied, for a
total of 576 mitochondria.
AAV production and delivery
A previous study has described that the deacetylation of
two Sirt3-targeted lysines (K926, K931) in the C-terminal
GTPase effector domain of the human OPA1 sequence
(NP_056375.2) results in the activation of OPA1 (41). These
two lysines are conserved between human and mouse, and
they correspond to the K944 and K949 lysines in the Mus
musculus OPA1 dynamin-like 120 kDa protein mitochondrial
isoform 1 precursor (NP_001186106.1). The cDNA for the
deacetylated form of mouse Opa1 was synthetized from
GenScript. It differs from thewtOpa1 (GI: 312836757) in two
base pair substitutions, c.A2831 > G and c.A2846 > G, and
codifies for a protein containing two arginins instead of the
conserved lysines K944 and K949 (K to R mutant plasmid).
The cDNA was cloned in the AAV vector backbone pZac2.1
(pZac2.1-mutOpa1; Gene Therapy Program, Penn Vector
core, University of Pennsylvania). To obtain the cDNA for the
WT mouse Opa1 (pZac2.1-wtOpa1), site-directed mutagen-
esis on pZac2.1-mutOpa1 with the QuickChange II XL Site-
Directed Mutagenesis Kit (#200521; Agilent Technologies,
Santa Clara, CA) was performed according to the manufac-
turer’s instructions. The following mutagenic primers were
used: fwd tgagaagaaggttaaattgctcactggcaaacgagttcagctggc;
rev gccagctgaactcgtttgccagtgagcaatttaaccttcttctca. The se-
quence of the full-length wtOpa1 was verified by Sanger se-
quencing on the 3730 DNA Analyzer (Applied Biosystem,
Foster City, CA).
pZac2.1-mutOpa1 and pZac2.1-wtOpa1 were packaged into
AAV capsid serotype 9 (AAV9-mutOpa1 and AAV9-wtOpa1,
respectively). Infectious vector stock was prepared by the
ICGEB AAV Vector Unit. Briefly, pZac2.1-mutOpa1 and
pZac2.1-wtOpa1 were cotransfected together with a pack-
aging/helper plasmid into HEK293 cells. Viral stocks were
obtained by CsCl2 gradient centrifugation. Titration of AAV
viral particles was performed by real-time PCR quantification
of the number of viral genomes, measured as cytomegalo-
virus copy number.
For animal studies, AAV viral vector constructs (1.3 · 1012
vector genomes per animal) were diluted in saline to a final
volume of 200 lL and administered to Sirt3-/- mice at 15 or
at 18–20 months of age via a single tail vein injection, and
animals were sacrificed 2 weeks or 3 months after AAV9
injection, respectively.
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X-Gal staining
Fresh heart specimens were frozen in optimum cutting
temperature compoundand stored at-80C.Three-micrometer
cryosections were fixed with acetone for 10min at 4C. X-Gal
staining was performed according to the manufacturer’s in-
structions (200384, in situ Beta-Galactosidase Staininig Kit;
Stratagene, SanDiego,CA). Sectionswere counterstainedwith
Harris’s hematoxylin and mounted in Faramount acqueous
mounting medium (S3025; Dako, Santa Clara, CA). Trans-
duction efficiency was expressed as percentage of X-Gal-
positive cardiomyocytes on the total number of cardiomyocytes,
evaluated in 38 random fields from three different areas of
the heart.
Citrate synthase activity
Mitochondrial content in cardiac tissues was evaluated by
assessing citrate synthase activity. Citrate synthase activity is
an accurate surrogate marker for detecting mitochondrial
content in tissues, and compared with other mitochondrial
mass indicators, it has the highest positive correlation with
morphometric analysis of mitochondria performed with
transmission electron microscopy (23). Hearts were washed
twice in 0.9% (w/v) sodium chloride solution and ho-
mogenized in CelLytic MT buffer (C3228; Sigma-Aldrich)
supplemented with protease inhibitor cocktail (P8340; Sigma-
Aldrich), and tissue disruption was completed by using a
blunt-ended needle and a syringe. As previously described
(35), the sample lysates were then centrifuged 16,000 g for
10min at 4C to remove detergent-insoluble material. Su-
pernatants were collected and total protein concentration
was determined using DC assay (5000112; Bio-Rad La-
boratories, Hercules, CA). Equal amounts of proteins (10 lg)
were analyzed by citrate synthase activity assay (CS072;
Sigma-Aldrich) according to the manufacturer’s protocol.
The citrate synthase activity was determined by the multi-
mode microplate reader TECAN Infinite M200 PRO (Te-
can Group Ltd., Mannedorf, Switzerland) at 412 nm under
temperature controlled on a kinetic program for 1.5min
every 10 s.
ATP content assay
Excised cardiac tissues were washed twice in 0.9% (w/v)
sodium chloride solution and homogenized in ATP assay
buffer (#K354; BioVision, Milpitas, CA), and tissue disrup-
tion was completed by using a blunt-ended needle and a sy-
ringe. As previously described (35), the lysates were
centrifuged 12,000 g for 10min at 4C to remove detergent-
insoluble material. Supernatants were harvested and total
protein concentration was determined using the DC assay
(5000112; Bio-Rad Laboratories). Then, supernatants were
deprived of proteins by using a deproteinizing preparation kit
(K808; BioVision) according to the manufacturer’s protocol.
ATP content assay (K354; BioVision) was then performed on
deproteinized samples according to the manufacturer’s pro-
tocol. The fluorescence intensities were determined by the
multimode microplate reader TECAN Infinite M200 PRO
(Tecan Group Ltd.) at an excitation wavelength of Ex 535 nm
and emission wavelength of Em 587 nm. Results were nor-
malized for the total protein concentration of each sample.
NAD+ content assay
Cardiac tissues were washed twice in 0.9% (w/v) sodium
chloride solution, homogenized in extraction buffer for NAD+
evaluation (KA1657; Abnova, Taipei City, Taiwan), and total
protein concentration was determined using DC assay (Bio-
Rad Laboratories). As previously described (35), samples were
then processed for the determination of the NAD+ content by
the multimode microplate reader TECAN Infinite M200 PRO
(Tecan Group Ltd.) at 565 nm at a controlled temperature for
15min according to the manufacturer’s protocol. Results were
normalized for total protein concentration of each sample.
Complex I activity assay
Cardiac tissues were washed twice in 0.9% (w/v) sodium
chloride solution, homogenized in detergent solution accord-
ing to the manufacturer’s instructions (ab109721 Assay Kit;
Abcam), and the total protein concentration was determined
using DC assay (Bio-Rad Laboratories). A total of 20lg of
heart extracts was then processed for the determination of
Complex I activity according to the manufacturer’s instruc-
tions (ab109721 Assay Kit; Abcam). Complex I activity in
each sample was determined by the multimode microplate
reader TECAN Infinite M200 PRO (Tecan Group Ltd.) at
450 nm under a kinetic program at a controlled temperature for
30min according to the manufacturer’s instructions.
Cardiac function and dobutamine stress test
Cardiac function in mice anesthetized with 2 vol% iso-
flurane in 0.5 L/min O2 was assessed by transthoracic
echocardiography using a commercially available echocar-
diographer equipped with a 12-MHz probe (MyLab30;
Esaote, Geneva, Italy), as previously described (44). Warmed
echo gel was placed on the shaved chest and each parameter
was measured using B-mode-guided M-mode imaging in the
parasternal short-axis view at the level of the papillary
muscles. Images were analyzed off-line in a blinded manner.
The global cardiac function was calculated as the percentage
of fractional shortening (LVFS %) of the left ventricle. Heart
rate and rhythmwere simultaneously monitored by three-lead
electrocardiogram (ECG). The cardiac function was evalu-
ated at rest and at peak after intraperitoneal injection of a
single bolus of dobutamine (1.5 lg/g of body weight), an
established method for assessing the myocardial contractile
reserve (10, 48). Echocardiographic scans and ECG record-
ings were repeated immediately after a single bolus injection
and then periodically over 10min, until the peak heart rate
response was reached and heart rate began to decline again.
ECG was recorded for 3min at rest and at the peak of do-
butamine stress.
Human iPSC-derived cardiomyocyte culture
Human iPSC-derived cardiomyocytes (C1006; Cellular
Dynamics International, Madison, WI) were seeded on 0.1%
gelatin-coated wells and cultured in a plating medium
(M1001; Cellular Dynamics International) at a density of
45,000 viable cells/cm2. At day 2, the medium was replaced
with maintenance medium (M1003; Cellular Dynamics In-
ternational) and changed at day 4 and 6.
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SIRT3 silencing and deacetylated Opa1 transfer
On day 7 postplating, iPSC-derived cardiomyocytes were
transfected with 50 nM Silencer Select predesigned siRNA
human SIRT3 (siSIRT3, s23768; Life Technologies, Carlsbad,
CA) or control nontarget siRNA (siNULL, Silencer Select
Negative Control #2 siRNA; Ambion, Carlsbad, CA) using
the TransIT-KO Transfection Reagent (MIR2150; Mirus Bio,
Madison, WI) according to the Cellular Dynamics Interna-
tional instructions. After 48 h of transfection, cells were used
for subsequent experiments.
In selected experiments, iPSC-derived cardiomyocytes
were transduced with 2· 106 multiplicity of infection/cells of
AAV9-mutOpa1 and 2 days later, SIRT3 silencing was per-
formed as above. AAV9-LacZ- transduced iPSC-derived cardi-
omyocytes transfected with siNULL were used as control. On
day 5 posttransduction, iPSC-derived cardiomyocytes were used
for the analysis of cell contractility and total protein extraction.
Real-time PCR
Human iPSC-derived cardiomyocytes were harvested in
TRIzol reagent (15596026; Invitrogen, Life Technologies),
and total RNA was extracted according to the manufacturer’s
instructions. Contaminating genomic DNA was removed by
RNase-free DNase (M6101; Promega, Madison, WI) for 1 h
at 37C. The first-strand cDNA (2.5 lg) was produced using a
SuperScript VILO cDNA Synthesis Kit (11754050; Life
Technologies) according to the manufacturer’s instruction.
To amplify cDNA of human SIRT3, we used the TaqMan
Universal PCR Master Mix (4304437; Applied Biosystems)
and inventoried TaqMan assays of the SIRT3 gene (FAM-
MBG probe Hs00202030_m1), and of the human HPRT
endogenous control (FAM-MGB probe, Hs99999909_m1)
according to the manufacturer’s instructions. PCR was per-
formed on the Viia7 Real-Time PCR System (Applied Bio-
systems). Data were analyzed using the 2-DDCT method and
presented as fold changes relative to siNULL cells.
MitoTracker analysis
To evaluate mitochondrial morphology, living iPSC-
derived cardiomyocytes were incubated with a 250 nM
fluorescent probe MitoTracker Red (M7512; Thermo
Fisher, Invitrogen) for 30min, at 37C, 5% CO2. Nuclei were
counterstained with NucBlue Live ReadyProbes (Hoechst;
R37605; Thermo Fisher, Invitrogen) according to the man-
ufacturer’s protocol. At the end of the probe incubations,
living cells were examined using the Cell Observer system
(Axio Observer.Z1; Zeiss Oberkochen, Germania) and mi-
tochondrial morphology was evaluated using the Mitochon-
drial Network Analysis toolset on Fiji software (50). Data
were normalized for the number of Hoechst-positive cells in
10 random fields per sample.
Cell contractility and FLUO-4 analysis
To detect cell contractility, living iPSC-derived cardio-
myocytes were seeded on 35-mm glass-bottomed dishes,
monitored under phase contrast using the Cell Observer
system (Axio Observer.Z1; Zeiss), and stably recorded for at
least 2min in different fields of the dish. For calcium anal-
ysis, the nonratiometric Fluo-4 dye Calcium Imaging Kit was
used (F10489; Thermo Fisher, Invitrogen), according to the
manufacturer’s protocol. Briefly, living iPSC-derived cardi-
omyocytes were incubated with Fluo-4 AM in Live Cell
Imaging Solution (Thermo Fisher, Invitrogen) supplemented
with 20mM glucose (Sigma-Aldrich) for 30min at 37C, 5%
CO2. At the end of probe incubations, living cells were rinsed
with the iCell Cardiomyocytes Maintenance Medium
(M1003; Cellular Dynamics International) and recorded for
at least 2min in different fields of the dish by the Cell Ob-
server system (Axio Observer.Z1; Zeiss).
Mitochondrial isolation from cardiac tissue
Mitochondria were isolated from mouse cardiac tissue
using the Qproteome Mitochondria Isolation Kit (37612;
Qiagen S.r.l., Milan, Italy) according to the manufacturer’s
protocol. Isolated mitochondria were solubilized in mito-
chondrial storage buffer (37612; Qiagen S.r.l.) and total
protein concentration was determined using the DC assay
(5000112; Bio-Rad Laboratories).
Protein extraction from human iPSC-derived
cardiomyocytes
For total protein extraction, human iPSC-derived cardio-
myocytes were washed twice in 0.9% (w/v) sodium chloride
solution and lysed by sonication in mammalian CelLytic M
lysis buffer (C2978; Sigma-Aldrich) supplemented with
protease inhibitor cocktail (P8340; Sigma-Aldrich). After
sonication, the sample lysates were centrifuged 16,000 g for
10min at 4C, and protein concentration was determined
using DC assay (Bio-Rad Laboratories).
Evaluation of OPA1 and SOD2 acetylation
OPA1 and SOD2 acetylation was determined by standard
Western blot analysis. Briefly, equal amounts of mitochon-
drial proteins from cardiac tissue (30 lg) or total extracts of
iPSC-derived cardiomyocytes (20 lg) were separated on
12% sodium dodecyl sulfate (SDS)/polyacrylamide gel elec-
trophoresis (PAGE) under reducing conditions and trans-
ferred to nitrocellulose membranes (Bio-Rad Laboratories).
After blocking with 5% BSA in Tris-buffered saline (TBS)
supplemented with 0.1% Tween-20, membranes were incu-
bated overnight at 4C with the following antibodies: rabbit
anti-acetylated-lysine (1:1000, BK9441; Cell Signaling) and
mouse anti-OPA1 antibody (1:1000, 612606; BDBioscience)
or sheep anti-SOD2 (1:1000, 574596; Merck Millipore). The
signals were visualized on an OdysseyFC Imaging System
(LiCor, Lincoln, NE) by infrared (IR) fluorescence using a
secondary goat anti-rabbit IRDye 680LT antibody (1:1000
FE3680210; LiCor) and a goat anti-mouse IRDye 800CW
(1:1000FE30926210; LiCor) or by enhanced chemiluminescence-
Western blotting detection reagent (Pierce, Thermo Fisher
Scientific, Inc.) using donkey anti-sheep (1:10,000 A3415;
Sigma-Aldrich) horseradish peroxidase secondary antibodies.
Mouse anti-VDAC (voltage-dependent anion channel [VDAC],
1:2000ab186321; Abcam) was used as sample-loading con-
trols in isolated mitochondria of the same membranes. Bands
were quantified by densitometry using the Image Studio Lite
5.0 (LiCor) software. OPA1 and SOD2 acetylation was ex-
pressed as the ratio between the band of acetylated lysine
colocalizing with the band corresponding to total OPA1 or
SOD2. Total OPA1 protein level was expressed as the ratio
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between the bands of OPA1 and VDAC. For any cropped
Western blot shown in the main body of the article, the full
uncut gels are found in Supplementary Figure S5.
Western blot analysis of ATP5I
Equal amounts of total extracts of iPSC-derived cardiomyo-
cytes (20lg) were separated on 12% SDS-PAGE under re-
ducing conditions and transferred to nitrocellulose membranes
(Bio-Rad Laboratories). After blocking with 5% BSA in TBS
supplemented with 0.1% Tween-20, membranes were incu-
bated with a rabbit anti-ATP5I antibody (1:1000 HPA035010;
Sigma-Aldrich).Mouse anti-VDAC (1:2000ab186321; Abcam)
was used as sample-loading controls in isolated mitochondria of
the same membranes. The signals were visualized on an
OdysseyFC Imaging System (LiCor) by IR fluorescence
using a secondary goat anti-rabbit IRDye 680LT antibody
(FE3680210; LiCor) and a goat anti-mouse IRDye 800CW
(FE30926210; LiCor), as appropriate. Bands were quantified
by densitometry using the Image Studio Lite (LiCor) 5.0
software. Total ATP5I protein level was expressed as the ratio
between the bands of ATP5I and VDAC. For any cropped
Western blot shown in the main body of the article, the full
uncut gels are found in Supplementary Figure S5.
Statistics
The significance level of difference between individual
groups was analyzed by the unpaired or paired Student’s t-test,
or analysis of variance with Tukey post hoc test comparisons,
and the statistical significance was defined as p-value of <0.05.
Results are given as mean– standard error of the mean (SEM).
Statistics for life span comparison between Sirt3-/- and
WT mice was evaluated through log-rank calculations. Max-
imum life span of Sirt3-/- andWTmice was compared bymeans
of a Laplace regression, considering the time by which 90% of
the mice had died (90th percentile of survival). The ‘Laplace’
package for STATA version 11 was retrieved for this purpose.
For the analysis of risk of cristae alignment alterations,
odds ratios with their 95% confidence intervals were esti-
mated taking into account familial dependence between ob-
servations with generalized estimated equations using the
GENMOD procedure in SAS, allowing the extension of
traditional linear model theory to generalized linear models
by allowing the mean of a population to depend on a linear
predictor through a nonlinear link function. In this article, we
investigated a binary outcome modeling approach using
PROC GENMODwith the link functions and aggregate, with
post hoc Bonferroni correction. Results are given as mean –
SEM, and the statistical significance was adjusted for mul-
tiple comparisons and was defined as p-value of <0.005.
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